Top

Published in:

15-12-2023 | Breast Cancer

Racial Disparities in Breast Cancer: from Detection to Treatment

Authors: JC Chen, Daniel G. Stover, Tarah J. Ballinger, Jose G. Bazan, Bryan P. Schneider, Barbara L. Andersen, William E. Carson, Samilia Obeng-Gyasi

Published in: Current Oncology Reports | Issue 1/2024

Abstract

Purpose of Review

Update on current racial disparities in the detection and treatment of breast cancer.

Recent Findings

Breast cancer remains the leading cause of cancer death among Black and Hispanic women. Mammography rates among Black and Hispanic women have surpassed those among White women, with studies now advocating for earlier initiation of breast cancer screening in Black women. Black, Hispanic, Asian, and American Indian and Alaskan Native women continue to experience delays in diagnosis and time to treatment. Further, racial discrepancies in receipt of guideline-concordant care, access to genetic testing and surgical reconstruction persist. Disparities in the initiation, completion, toxicity, and efficacy of chemotherapy, endocrine therapy, and targeted drug therapy remain for racially marginalized women.

Summary

Efforts to evaluate the impact of race and ethnicity across the breast cancer spectrum are increasing, but knowledge gaps remain and further research is necessary to reduce the disparity gap.

• Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41. https://doi.org/10.3322/caac.21754. American Cancer Society’s most recent update on breast cancer statistics including incidence, screening behaviors, mortality, and survival.CrossRefPubMed

Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American/Black People 2022. CA Cancer J Clin. 2022;72(3):202–29. https://doi.org/10.3322/caac.21718.CrossRefPubMed

Duffy SW, Tabár L, Yen AM, Dean PB, Smith RA, Jonsson H, et al. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer. 2020;126(13):2971–9. https://doi.org/10.1002/cncr.32859.CrossRefPubMed

Ahmed AT, Welch BT, Brinjikji W, Farah WH, Henrichsen TL, Murad MH, et al. Racial disparities in screening mammography in the United States: a systematic review and meta-analysis. J Am Coll Radiol. 2017;14(2):157-65.e9. https://doi.org/10.1016/j.jacr.2016.07.034.CrossRefPubMed

Hensing WL, Poplack SP, Herman CR, Sutcliffe S, Colditz GA, Ademuyiwa FO. Racial differences in no-show rates for screening mammography. Cancer. 2021;127(11):1857–63. https://doi.org/10.1002/cncr.33435.CrossRefPubMed

Cancer Prevention & Early Detection Facts & Figures 2023-2024. Atlanta: American Cancer Society; 2023-2024.

Swami N, Nguyen T, Dee EC, Franco I, Baez YA, Lapen K, et al. Disparities in primary breast cancer stage at presentation among Hispanic subgroups. Ann Surg Oncol. 2022;29(13):7977–87. https://doi.org/10.1245/s10434-022-12302-9.CrossRefPubMed

•• Fayanju OM, Edmonds CE, Reyes SA, Arciero C, Bea VJ, Crown A, et al. The landmark series-addressing disparities in breast cancer screening: new recommendations for black women. Ann Surg Oncol. 2023;30(1):58–67. https://doi.org/10.1245/s10434-022-12535-8. An overview of epidemiologic factors associated with breast cancer among Black women and their implications on screening, specifically reviewing evidence behind their recommendations to stratify risk and start screening earlier for Black women.CrossRefPubMed

Chen T, Kharazmi E, Fallah M. Race and ethnicity-adjusted age recommendation for initiating breast cancer screening. JAMA Netw Open. 2023;6(4): e238893. https://doi.org/10.1001/jamanetworkopen.2023.8893.CrossRefPubMedPubMedCentral

10.

La Frinere-Sandoval QNNB, Cubbin C, DiNitto DM. Racial and ethnic disparities in cervical and breast cancer screenings by nativity and length of U.S. residence. Ethn Health. 2023:1–17. https://doi.org/10.1080/13557858.2023.2174254.

11.

Lawson MB, Bissell MCS, Miglioretti DL, Eavey J, Chapman CH, Mandelblatt JS, et al. Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity. JAMA Oncol. 2022;8(8):1115–26. https://doi.org/10.1001/jamaoncol.2022.1990.CrossRefPubMedPubMedCentral

12.

Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS. Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups. Cancer. 2017;123(18):3468–75. https://doi.org/10.1002/cncr.30756.CrossRefPubMed

13.

Ramirez AG, Pérez-Stable EJ, Talavera GA, Penedo FJ, Carrillo JE, Fernandez ME, et al. Time to definitive diagnosis of breast cancer in Latina and non-Hispanic white women: the six cities study. Springerplus. 2013;2(1):84. https://doi.org/10.1186/2193-1801-2-84.CrossRefPubMedPubMedCentral

14.

Dontchos BN, Achibiri J, Mercaldo SF, Wang GX, Lamb LR, Miles RC, et al. Disparities in same-day diagnostic imaging in breast cancer screening: impact of an immediate-read screening mammography program implemented during the COVID-19 pandemic. AJR Am J Roentgenol. 2022;218(2):270–8. https://doi.org/10.2214/AJR.21.26597.CrossRefPubMed

15.

Dontchos BN, Narayan AK, Seidler M, Mercaldo SF, Miles RC, Ebert E, et al. Impact of a same-day breast biopsy program on disparities in time to biopsy. J Am Coll Radiol. 2019;16(11):1554–60. https://doi.org/10.1016/j.jacr.2019.05.011.CrossRefPubMed

16.

Jackson DK, Li Y, Eskander MF, Tsung A, Oppong BA, Bhattacharyya O, et al. Racial disparities in low-value surgical care and time to surgery in high-volume hospitals. J Surg Oncol. 2021;123(2):676–86. https://doi.org/10.1002/jso.26320.CrossRefPubMed

17.

Zaveri S, Nevid D, Ru M, Moshier E, Pisapati K, Reyes SA, et al. Racial disparities in time to treatment persist in the setting of a comprehensive breast center. Ann Surg Oncol. 2022;29(11):6692–703. https://doi.org/10.1245/s10434-022-11971-w.CrossRefPubMed

18.

Sukniam K, Kasbi AA, Ashary MA, Popp K, Attwood K, George A, et al. Disparities in time to treatment for breast cancer. Anticancer Res. 2022;42(12):5813–8. https://doi.org/10.21873/anticanres.16088.CrossRefPubMed

19.

Stabellini N, Cullen J, Cao L, Shanahan J, Hamerschlak N, Waite K, et al. Racial disparities in breast cancer treatment patterns and treatment related adverse events. Sci Rep. 2023;13(1):1233. https://doi.org/10.1038/s41598-023-27578-4.ADSCrossRefPubMedPubMedCentral

20.

Corradini S, Reitz D, Pazos M, Schönecker S, Braun M, Harbeck N, et al. Mastectomy or breast-conserving therapy for early breast cancer in real-life clinical practice: outcome comparison of 7565 cases. Cancers (Basel). 2019;11(2). https://doi.org/10.3390/cancers11020160.

21.

Chervu N, Darbinian K, Sakowitz S, Verma A, Bakhtiyar SS, Shuch BM, et al. Disparate utilization of breast conservation therapy in the surgical management of early-stage breast cancer. Clin Breast Cancer. 2023. https://doi.org/10.1016/j.clbc.2023.04.008.CrossRefPubMed

22.

Relation T, Obeng-Gyasi S, Bhattacharyya O, Li Y, Eskander MF, Tsung A, et al. Racial differences in response to neoadjuvant chemotherapy: impact on breast and axillary surgical management. Ann Surg Oncol. 2021;28(11):6489–97. https://doi.org/10.1245/s10434-021-09657-w.CrossRefPubMedPubMedCentral

23.

Fwelo P, Nwosu KOS, Adekunle TE, Afolayan O, Ahaiwe O, Ojaruega AA, et al. Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: mediating impact on mortality. Breast Cancer Res Treat. 2023;199(3):511–31. https://doi.org/10.1007/s10549-023-06941-z.CrossRefPubMed

24.

• Yu AYL, Thomas SM, DiLalla GD, Greenup RA, Hwang ES, Hyslop T, et al. Disease characteristics and mortality among Asian women with breast cancer. Cancer. 2022;128(5):1024–37. https://doi.org/10.1002/cncr.34015. Evaluation of breast cancer characteristics and outcomes amongst Asian subgroups, highlighting the necessity to disaggregate Asian women.CrossRefPubMed

25.

Advani P, Bondy M, Thompson PA, Martínez ME, Nodora JN, Vernon SW, et al. Impact of acculturation on breast cancer treatment and survivorship care among Mexican American patients in Texas. J Cancer Surviv. 2018;12(5):659–68. https://doi.org/10.1007/s11764-018-0703-y.CrossRefPubMedPubMedCentral

26.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33. https://doi.org/10.1016/S1470-2045(10)70207-2.CrossRefPubMedPubMedCentral

27.

Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg. 2014;149(8):788–96. https://doi.org/10.1001/jamasurg.2014.23.CrossRefPubMedPubMedCentral

28.

Grimmer L, Liederbach E, Velasco J, Pesce C, Wang CH, Yao K. Variation in contralateral prophylactic mastectomy rates according to racial groups in young women with breast cancer, 1998 to 2011: a report from the national cancer data base. J Am Coll Surg. 2015;221(1):187–96. https://doi.org/10.1016/j.jamcollsurg.2015.03.033.CrossRefPubMed

29.

Scheepens JCC, Veer LV, Esserman L, Belkora J, Mukhtar RA. Contralateral prophylactic mastectomy: a narrative review of the evidence and acceptability. Breast. 2021;56:61–9. https://doi.org/10.1016/j.breast.2021.02.003.CrossRefPubMedPubMedCentral

30.

Kim Y, McCarthy AM, Bristol M, Armstrong K. Disparities in contralateral prophylactic mastectomy use among women with early-stage breast cancer. NPJ Breast Cancer. 2017;3:2. https://doi.org/10.1038/s41523-017-0004-z.CrossRefPubMedPubMedCentral

31.

Verdial FC, Bartek MA, Anderson BO, Javid SH. Genetic testing and surgical treatment after breast cancer diagnosis: results from a national online cohort. J Surg Oncol. 2021;123(7):1504–12. https://doi.org/10.1002/jso.26372.CrossRefPubMedPubMedCentral

32.

Nikolaidis C, Duquette D, Mendelsohn-Victor KE, Anderson B, Copeland G, Milliron KJ, et al. Disparities in genetic services utilization in a random sample of young breast cancer survivors. Genet Med. 2019;21(6):1363–70. https://doi.org/10.1038/s41436-018-0349-1.CrossRefPubMed

33.

Reid S, Cadiz S, Pal T. Disparities in genetic testing and care among black women with hereditary breast cancer. Curr Breast Cancer Rep. 2020;12(3):125–31. https://doi.org/10.1007/s12609-020-00364-1.CrossRefPubMedPubMedCentral

34.

Peterson JM, Pepin A, Thomas R, Biagi T, Stark E, Sparks AD, et al. Racial disparities in breast cancer hereditary risk assessment referrals. J Genet Couns. 2020;29(4):587–93. https://doi.org/10.1002/jgc4.1250.CrossRefPubMed

35.

Centers for Medicare & Medicaid Services. Women's Health and Cancer Rights Act (WHCRA) Women's Health and Cancer Rights Act (WHCRA). 2023. CMS.gov. Retrieved November 10, 2023, from https://www.cms.gov/cciio/programs-and-initiatives/other-insurance-protections/whcra_factsheet

36.

Sergesketter AR, Thomas SM, Lane WO, Orr JP, Shammas RL, Fayanju OM, et al. Decline in racial disparities in postmastectomy breast reconstruction: a surveillance, epidemiology, and end results analysis from 1998 to 2014. Plast Reconstr Surg. 2019;143(6):1560–70. https://doi.org/10.1097/PRS.0000000000005611.CrossRefPubMedPubMedCentral

37.

Lee C, Sunu C, Pignone M. Patient-reported outcomes of breast reconstruction after mastectomy: a systematic review. J Am Coll Surg. 2009;209(1):123–33. https://doi.org/10.1016/j.jamcollsurg.2009.02.061.CrossRefPubMedPubMedCentral

38.

Cordova LZ, Hunter-Smith DJ, Rozen WM. Patient reported outcome measures (PROMs) following mastectomy with breast reconstruction or without reconstruction: a systematic review. Gland Surg. 2019;8(4):441–51. https://doi.org/10.21037/gs.2019.07.02.CrossRefPubMedPubMedCentral

39.

Xie Y, Tang Y, Wehby GL. Federal health coverage mandates and health care utilization: the case of the women’s health and cancer rights act and use of breast reconstruction surgery. J Womens Health (Larchmt). 2015;24(8):655–62. https://doi.org/10.1089/jwh.2014.5057.CrossRefPubMed

40.

Hamad A, Li Y, Tsung A, Oppong B, Eskander MF, Bhattacharyya O, et al. Hispanic ethnicity and breast cancer: disaggregating surgical management and mortality by race. J Racial Ethn Health Disparities. 2022;9(4):1568–76. https://doi.org/10.1007/s40615-021-01096-3.CrossRefPubMed

41.

Johnstone T, Thawanyarat K, Rowley M, Francis S, Camacho JM, Singh D, et al. Racial Disparities in Postoperative Breast Reconstruction Outcomes: A National Analysis. J Racial Ethn Health Disparities. 2023. https://doi.org/10.1007/s40615-023-01599-1.CrossRefPubMed

42.

Mets EJ, Chouairi FK, Gabrick KS, Avraham T, Alperovich M. Persistent disparities in breast cancer surgical outcomes among hispanic and African American patients. Eur J Surg Oncol. 2019;45(4):584–90. https://doi.org/10.1016/j.ejso.2019.01.016.CrossRefPubMed

43.

Comprehensive Breast Reconstruction Act of 2021, H.R.469, 117th Congress, 2021.

44.

Dehal A, Abbas A, Johna S. Racial disparities in clinical presentation, surgical treatment and in-hospital outcomes of women with breast cancer: analysis of nationwide inpatient sample database. Breast Cancer Res Treat. 2013;139(2):561–9. https://doi.org/10.1007/s10549-013-2567-1.CrossRefPubMed

45.

Akinyemiju TF, Vin-Raviv N, Chavez-Yenter D, Zhao X, Budhwani H. Race/ethnicity and socio-economic differences in breast cancer surgery outcomes. Cancer Epidemiol. 2015;39(5):745–51. https://doi.org/10.1016/j.canep.2015.07.010.CrossRefPubMed

46.

Oskar S, Nelson JA, Hicks MEV, Seier MSKP, Tan KS, Chu JJ, et al. The impact of race on perioperative and patient-reported outcomes following autologous breast reconstruction. Plast Reconstr Surg. 2022;149(1):15–27. https://doi.org/10.1097/PRS.0000000000008633.CrossRefPubMedPubMedCentral

47.

Montagna G, Zhang J, Sevilimedu V, Charyn J, Abbate K, Gomez EA, et al. Risk factors and racial and ethnic disparities in patients with breast cancer-related lymphedema. JAMA Oncol. 2022;8(8):1195–200. https://doi.org/10.1001/jamaoncol.2022.1628.CrossRefPubMedPubMedCentral

48.

Deldar RM, Spoer DM, Gupta NM, Towfighi PB, Boisvert MM, Wehner PM, et al. Prophylactic lymphovenous bypass at the time of axillary lymph node dissection decreases rates of lymphedema. Ann Surg Open. 2023;4(2): e278. https://doi.org/10.1097/AS9.0000000000000278.CrossRefPubMedPubMedCentral

49.

Jørgensen MG, Toyserkani NM, Sørensen JA. The effect of prophylactic lymphovenous anastomosis and shunts for preventing cancer-related lymphedema: a systematic review and meta-analysis. Microsurgery. 2018;38(5):576–85. https://doi.org/10.1002/micr.30180.CrossRefPubMed

50.

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41. https://doi.org/10.1056/NEJMoa022152.CrossRefPubMed

51.

Yeboa DN, Xu X, Jones BA, Soulos P, Gross C, Yu JB. Trend in age and racial disparities in the receipt of postlumpectomy radiation therapy for stage I breast cancer: 2004–2009. Am J Clin Oncol. 2016;39(6):568–74. https://doi.org/10.1097/COC.0000000000000094.CrossRefPubMed

52.

Parekh A, Fu W, Hu C, Shen CJ, Alcorn S, Rao AD, et al. Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database. Breast Cancer Res Treat. 2018;172(1):201–8. https://doi.org/10.1007/s10549-018-4881-0.CrossRefPubMed

53.

Wakefield DV, Carnell M, Dove APH, Edmonston DY, Garner WB, Hubler A, et al. Location as destiny: identifying geospatial disparities in radiation treatment interruption by neighborhood, race, and insurance. Int J Radiat Oncol Biol Phys. 2020;107(4):815–26. https://doi.org/10.1016/j.ijrobp.2020.03.016.CrossRefPubMed

54.

Lamm R, Woodward SG, Varshney K, Lyons W, Anne PR, George BJ, et al. A comparison of timely completion of hypofractionated and traditional adjuvant radiation therapy in early-stage breast cancer: evidence of impact on reducing racial and socioeconomic disparities. Surgery. 2022;172(1):31–40. https://doi.org/10.1016/j.surg.2022.03.019.CrossRefPubMed

55.

Dee EC, Taunk NK, Chino FL, Deville C, McClelland S, Muralidhar V, et al. Shorter radiation regimens and treatment noncompletion among patients with breast and prostate cancer in the united states: an analysis of racial disparities in access and quality. JCO Oncol Pract. 2023;19(2):e197–212. https://doi.org/10.1200/OP.22.00383.CrossRefPubMed

56.

• Chapman CH, Jagsi R, Griffith KA, Moran JM, Vicini F, Walker E, et al. Mediators of racial disparities in heart dose among whole breast radiotherapy patients. J Natl Cancer Inst. 2022;114(12):1646–55. https://doi.org/10.1093/jnci/djac120. This study uses a statewide database to evaluate racial differences in receipt of breast radiotherapy, ultimately finding that Black and Asian women receive higher cardiac doses leading to greater cardiac events and deaths compared to White women.CrossRefPubMedPubMedCentral

57.

Jagsi R, Griffith KA, Vicini F, Boike T, Burmeister J, Dominello MM, et al. Toward improving patients’ experiences of acute toxicity from breast radiotherapy: insights from the analysis of patient-reported outcomes in a large multicenter cohort. J Clin Oncol. 2020;38(34):4019–29. https://doi.org/10.1200/JCO.20.01703.CrossRefPubMedPubMedCentral

58.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26. https://doi.org/10.1056/NEJMoa041588.CrossRefPubMed

59.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34. https://doi.org/10.1200/JCO.2005.04.7985.CrossRefPubMed

60.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. https://doi.org/10.1056/NEJMoa1804710.CrossRefPubMedPubMedCentral

61.

• Kantor O, King TA, Freedman RA, Mayer EL, Chavez-MacGregor M, Korde LA, et al. Racial and ethnic disparities in locoregional recurrence among patients with hormone receptor-positive, node-negative breast cancer: a post hoc analysis of the TAILORx randomized clinical trial. JAMA Surg. 2023;158(6):583–91. https://doi.org/10.1001/jamasurg.2023.0297. Post hoc analysis of TAILORx clinical trial noting racial discrepancies in locoregional recurrence rate, even upon adjustment for patient, tumor, and treatment factors, overall suggesting persistent differences despite similar access to care.CrossRefPubMed

62.

Hoskins KF, Danciu OC, Ko NY, Calip GS. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol. 2021;7(3):370–8. https://doi.org/10.1001/jamaoncol.2020.7320.CrossRefPubMed

63.

Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, et al. Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2021;113(4):390–9. https://doi.org/10.1093/jnci/djaa148.CrossRefPubMed

64.

Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, et al. The 21-gene recurrence score assay for node-positive, early-stage breast cancer and impact of RxPONDER trial on chemotherapy decision-making: have clinicians already decided? J Natl Compr Canc Netw. 2017;15(4):494–503. https://doi.org/10.6004/jnccn.2017.0049.CrossRefPubMed

65.

Abdou Y, WE Barlow, Gralow JR. Race and clinical outcomes in the RxPONDER Trial (SWOG S1007): clinical trial Rx for positive node, endocrine responsive breast cancer. 2022 San Antonio Breast Cancer Symposium. San Antonio, TX. 2022.

66.

•• Reid S, Haddad D, Tezak A, Weidner A, Wang X, Mautz B, et al. Impact of molecular subtype and race on HR+, HER2- breast cancer survival. Breast Cancer Res Treat. 2021;189(3):845–52. https://doi.org/10.1007/s10549-021-06342-0. This study evaluates PAM50-based genomic signatures amongst HR+, HER2- breast cancer, overall finding racial differences in subtypes that may contribute to mortality discrepancies. These findings also suggest the possible need to re-structure the current classification of breast cancer.CrossRefPubMedPubMedCentral

67.

Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, et al. Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol. 2015;33(36):4267–76. https://doi.org/10.1200/JCO.2015.63.7801.CrossRefPubMed

68.

Shubeck S, Zhao F, Howard FM, Olopade OI, Huo D. Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US. JAMA Netw Open. 2023;6(3): e235834. https://doi.org/10.1001/jamanetworkopen.2023.5834.CrossRefPubMedPubMedCentral

69.

Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, et al. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in black and white women with early-stage breast cancer. Breast Cancer Res Treat. 2023;200(1):75–83. https://doi.org/10.1007/s10549-023-06943-x.CrossRefPubMedPubMedCentral

70.

Zhao F, Miyashita M, Hattori M, Yoshimatsu T, Howard F, Kaneva K, et al. Racial disparities in pathological complete response among patients receiving neoadjuvant chemotherapy for early-stage breast cancer. JAMA Netw Open. 2023;6(3): e233329. https://doi.org/10.1001/jamanetworkopen.2023.3329.CrossRefPubMedPubMedCentral

71.

Knisely AT, Michaels AD, Mehaffey JH, Hassinger TE, Krebs ED, Brenin DR, et al. Race is associated with completion of neoadjuvant chemotherapy for breast cancer. Surgery. 2018;164(2):195–200. https://doi.org/10.1016/j.surg.2018.03.011.CrossRefPubMed

72.

Vo JB, Ramin C, Lawrence WR, Barac A, Ho KL, Rhee J, et al. Racial and ethnic disparities in treatment-related heart disease mortality among US breast cancer survivors. JNCI Cancer Spectr. 2023;7(2). https://doi.org/10.1093/jncics/pkad024.

73.

Schneider BP, Shen F, Jiang G, O'Neill A, Radovich M, Li L, et al. Impact of genetic ancestry on outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol. 2017;2017. https://doi.org/10.1200/PO.17.00059.

74.

Hu X, Kaplan CM, Martin MY, Walker MS, Stepanski E, Schwartzberg LS, et al. Race differences in patient-reported symptoms during chemotherapy among women with early-stage hormone receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev. 2023;32(2):167–74. https://doi.org/10.1158/1055-9965.EPI-22-0692.CrossRefPubMedPubMedCentral

75.

Yee MK, Sereika SM, Bender CM, Brufsky AM, Connolly MC, Rosenzweig MQ. Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. Cancer. 2017;123(11):2061–9. https://doi.org/10.1002/cncr.30575.CrossRefPubMed

76.

Samuel CA, Schaal J, Robertson L, Kollie J, Baker S, Black K, et al. Racial differences in symptom management experiences during breast cancer treatment. Support Care Cancer. 2018;26(5):1425–35. https://doi.org/10.1007/s00520-017-3965-4.CrossRefPubMed

77.

Emerson MA, Achacoso NS, Benefield HC, Troester MA, Habel LA. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors. Cancer. 2021;127(11):1847–56. https://doi.org/10.1002/cncr.33423.CrossRefPubMed

78.

Sheppard VB, de Mendoza AH, He J, Jennings Y, Edmonds MC, Oppong BA, et al. Initiation of adjuvant endocrine therapy in black and white women with breast cancer. Clin Breast Cancer. 2018;18(5):337-46.e1. https://doi.org/10.1016/j.clbc.2017.12.002.CrossRefPubMed

79.

Sheppard VB, Sutton AL, Hurtado-de-Mendoza A, He J, Dahman B, Edmonds MC, et al. Race and patient-reported symptoms in adherence to adjuvant endocrine therapy: a report from the women’s hormonal initiation and persistence study. Cancer Epidemiol Biomarkers Prev. 2021;30(4):699–709. https://doi.org/10.1158/1055-9965.EPI-20-0604.CrossRefPubMedPubMedCentral

80.

Yanez B, Gray RJ, Sparano JA, Carlos RC, Sadigh G, Garcia SF, et al. Association of modifiable risk factors with early discontinuation of adjuvant endocrine therapy: a post hoc analysis of a randomized clinical trial. JAMA Oncol. 2021;7(8):1–7. https://doi.org/10.1001/jamaoncol.2021.1693.CrossRefPubMedPubMedCentral

81.

Hu X, Walker MS, Stepanski E, Kaplan CM, Martin MY, Vidal GA, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8): e2225485. https://doi.org/10.1001/jamanetworkopen.2022.25485.CrossRefPubMedPubMedCentral

82.

Wheeler SB, Spencer J, Pinheiro LC, Murphy CC, Earp JA, Carey L, et al. Endocrine therapy nonadherence and discontinuation in black and white women. J Natl Cancer Inst. 2019;111(5):498–508. https://doi.org/10.1093/jnci/djy136.CrossRefPubMed

83.

Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, et al. Breast cancer patients’ insurance status and residence zip code correlate with early discontinuation of endocrine therapy: an analysis of the ECOG-ACRIN TAILORx trial. Cancer. 2021;127(14):2545–52. https://doi.org/10.1002/cncr.33527.CrossRefPubMed

84.

Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, et al. Assessment of racial disparity in survival outcomes for early hormone receptor-positive breast cancer after adjusting for insurance status and neighborhood deprivation: a post hoc analysis of a randomized clinical trial. JAMA Oncol. 2022;8(4):579–86. https://doi.org/10.1001/jamaoncol.2021.7656.CrossRefPubMedPubMedCentral

85.

Hwang GS, Paranjpe R, Opsomer C, Lu K, Abajue U, Abughosh S, et al. Oral endocrine therapy agent, race/ethnicity, and time on therapy predict adherence in breast cancer patients in a large academic institution. Clin Breast Cancer. 2020;20(6):520–6. https://doi.org/10.1016/j.clbc.2020.06.004.CrossRefPubMed

86.

Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluation of the quality of adjuvant endocrine therapy delivery for breast cancer care in the United States. JAMA Oncol. 2017;3(7):928–35. https://doi.org/10.1001/jamaoncol.2016.6380.CrossRefPubMedPubMedCentral

87.

Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB. Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol. 2016;34(17):2003–9. https://doi.org/10.1200/JCO.2015.65.8716.CrossRefPubMedPubMedCentral

88.

Al-Sadawi M, Hussain Y, Copeland-Halperin RS, Tobin JN, Moskowitz CS, Dang CT, et al. Racial and socioeconomic disparities in cardiotoxicity among women with her2-positive breast cancer. Am J Cardiol. 2021;147:116–21. https://doi.org/10.1016/j.amjcard.2021.02.013.CrossRefPubMedPubMedCentral

89.

Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, et al. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer. 2018;124(9):1904–11. https://doi.org/10.1002/cncr.31260.CrossRefPubMed

90.

Lao C, Lawrenson R, Edwards M, Campbell I. Treatment and survival of Asian women diagnosed with breast cancer in New Zealand. Breast Cancer Res Treat. 2019;177(2):497–505. https://doi.org/10.1007/s10549-019-05310-z.CrossRefPubMed

91.

Alvarez A, Bernal AM, Anampa J. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2023;198(1):75–88. https://doi.org/10.1007/s10549-022-06847-2.CrossRefPubMed

92.

Schreier A, Munoz-Arcos L, Alvarez A, Sparano JA, Anampa JD. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors. Breast Cancer Res Treat. 2022;194(2):337–51. https://doi.org/10.1007/s10549-022-06574-8.CrossRefPubMed

93.

Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;174(1):271–8. https://doi.org/10.1007/s10549-018-5054-x.CrossRefPubMed

94.

Sohn YJ, Chang CY, Miles RC. Current gaps in breast cancer screening among Asian and Asian American women in the United States. J Am Coll Radiol. 2021;18(10):1376–83. https://doi.org/10.1016/j.jacr.2021.06.002.CrossRefPubMed

95.

Taparra K, Dee EC, Dao D, Patel R, Santos P, Chino F. Disaggregation of Asian American and Pacific Islander women with stage 0-ii breast cancer unmasks disparities in survival and surgery-to-radiation intervals: a national cancer database analysis from 2004 to 2017. JCO Oncol Pract. 2022;18(8):e1255–64. https://doi.org/10.1200/OP.22.00001.CrossRefPubMedPubMedCentral

96.

Cobb RJ, Thomas CS, Laster Pirtle WN, Darity WA. Self-identified race, socially assigned skin tone, and adult physiological dysregulation: assessing multiple dimensions of “race” in health disparities research. SSM Popul Health. 2016;2:595–602. https://doi.org/10.1016/j.ssmph.2016.06.007.CrossRefPubMedPubMedCentral

97.

Chen JC, Pawlik T, Kelly EP, Obeng-Gyasi S. Intersectionality in patients with cancer: who should care and why? Future Oncol. 2022;18(38):4137–40. https://doi.org/10.2217/fon-2022-0992.CrossRefPubMed

Title: Racial Disparities in Breast Cancer: from Detection to Treatment
Authors: JC Chen
Daniel G. Stover
Tarah J. Ballinger
Jose G. Bazan
Bryan P. Schneider
Barbara L. Andersen
William E. Carson
Samilia Obeng-Gyasi
Publication date: 15-12-2023
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Current Oncology Reports / Issue 1/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01472-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2024

Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum

Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?

Male Breast Cancer: a Review on Diagnosis, Treatment, and Survivorship

Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies

Surgery for Recurrent Epithelial Ovarian Cancer

Resectability versus Operability in Early-Stage Non-Small Cell Lung Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer